Erebouni Medical Center

Clinical researches

Double-Blind, Randomized, Parallel, Placebo Controlled Study Examining the Effect of Cross-linked Polyelectrolyte (CLP) in Heart Failure Patients with Chronic Kidney Disease
– International Multicenter double-blind placebo – controlled research (number of protocol CTST - 21), organized by Sorbent Therapeutics company (Inc. 710 Lakeway Drive, Suite 290 Sunnyvalley, Ca 94085 USA, USA) – 2009 – 2011; scientific article in European Journal of Heart Failure (see the list of scientific works of Hayrapetyan G.G.), lectures on the Congress of European Association of Cardiology for cardiac failure 2011.
Айрапетян Г.Г. / Роль - Principal Investigator
Effects of Ivabradine in patients with stable coronary artery disease without clinical heart failure
A randomised double-blind Placebo-controlled international multicentre study. Study assessing the morbi-mortality benefits of the If inhibitor Ivabradine in patients with coronary artery disease (SIGNIFY study, study protocol CL3-16257-083)
Servier Laboratories
Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradine compared to placebo on top of a background therapy with a calcium antagonist (amlodipine or nifedipine) in patients with stable angina pectoris
A 6-week randomised double-blind parallel-group international multicentre study (study protocol N CL3 16257 068). S-16257-2– IVABRADINE Short code title: CL3-16257-PO-C-Placebo-1240 P-Stable effort angina/ Calcium antagonist
Айрапетян Г.Г. / Роль - Principal Investigator
Heart failure
Hayrapetyan A.G., Saghatelyan M.G., Poghosyan D.D.
1 2 3 4 5
Back to top